Fangjian Guo1, Yong-Fang Kuo2, Abbey B Berenson3. 1. Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas; Center for Interdisciplinary Research in Women's Health, University of Texas Medical Branch, Galveston, Texas. Electronic address: faguo@utmb.edu. 2. Center for Interdisciplinary Research in Women's Health, University of Texas Medical Branch, Galveston, Texas; Office of Biostatistics, Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, Texas; Institute for Translational Science, University of Texas Medical Branch, Galveston, Texas. 3. Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas; Center for Interdisciplinary Research in Women's Health, University of Texas Medical Branch, Galveston, Texas.
Abstract
INTRODUCTION: The U.S. Preventive Services Task Force changed breast cancer screening guidelines in November 2009 for mammograms in women aged 40-49 and 50-74 years. The aim of this study was to assess the impact of the 2009 guideline changes on breast cancer incidence by stage among women aged 40-49 and 50-74 years in the U.S. METHODS: This was a cross-sectional trend analysis of the impact of 2009 guideline change on breast cancer incidence by stage, using data from the National Program for Cancer Registries and Surveillance, Epidemiology, and End Results Incidence-U.S. Cancer Statistics 2001-2014 database among women aged 40-74 years. Incidence was age adjusted to the U.S. standard population. Data were collected in 2001-2014, released in 2017, and analyzed in 2018. RESULTS: Among women aged 40-49 years, the 4-year average annual incidence of breast cancer increased slightly in 2011-2014 for in situ, localized, and distant cancer, but decreased for regional cancer compared with the incidence in 2006-2009. Among women aged 50-74 years, the 4-year average annual incidence of breast cancer increased in 2011-2014 for localized and distant cancer, but decreased for in situ and regional cancer. Joinpoint analyses revealed that annual percentage changes decreased after 2009 for distant cancer among both women aged 40-49 and 50-74 years. The composition of breast cancer by stage was similar between 2006-2009 and 2011-2014 among both women aged 40-49 and 50-74 years. CONCLUSIONS: Changes in breast cancer screening by the 2009 U.S. Preventive Services Task Force guidelines had little immediate adverse effects on the stage distribution of breast cancer diagnoses in the U.S. Monitoring the incidence by cancer stages over time is needed.
INTRODUCTION: The U.S. Preventive Services Task Force changed breast cancer screening guidelines in November 2009 for mammograms in women aged 40-49 and 50-74 years. The aim of this study was to assess the impact of the 2009 guideline changes on breast cancer incidence by stage among women aged 40-49 and 50-74 years in the U.S. METHODS: This was a cross-sectional trend analysis of the impact of 2009 guideline change on breast cancer incidence by stage, using data from the National Program for Cancer Registries and Surveillance, Epidemiology, and End Results Incidence-U.S. Cancer Statistics 2001-2014 database among women aged 40-74 years. Incidence was age adjusted to the U.S. standard population. Data were collected in 2001-2014, released in 2017, and analyzed in 2018. RESULTS: Among women aged 40-49 years, the 4-year average annual incidence of breast cancer increased slightly in 2011-2014 for in situ, localized, and distant cancer, but decreased for regional cancer compared with the incidence in 2006-2009. Among women aged 50-74 years, the 4-year average annual incidence of breast cancer increased in 2011-2014 for localized and distant cancer, but decreased for in situ and regional cancer. Joinpoint analyses revealed that annual percentage changes decreased after 2009 for distant cancer among both women aged 40-49 and 50-74 years. The composition of breast cancer by stage was similar between 2006-2009 and 2011-2014 among both women aged 40-49 and 50-74 years. CONCLUSIONS: Changes in breast cancer screening by the 2009 U.S. Preventive Services Task Force guidelines had little immediate adverse effects on the stage distribution of breast cancer diagnoses in the U.S. Monitoring the incidence by cancer stages over time is needed.
Authors: Amir Qaseem; Vincenza Snow; Katherine Sherif; Mark Aronson; Kevin B Weiss; Douglas K Owens Journal: Ann Intern Med Date: 2007-04-03 Impact factor: 25.391
Authors: Carol E DeSantis; Stacey A Fedewa; Ann Goding Sauer; Joan L Kramer; Robert A Smith; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2015-10-29 Impact factor: 508.702
Authors: Brian L Sprague; Kenyon C Bolton; John L Mace; Sally D Herschorn; Ted A James; Pamela M Vacek; Donald L Weaver; Berta M Geller Journal: Radiology Date: 2013-10-28 Impact factor: 11.105
Authors: Sam Harper; John Lynch; Stephen C Meersman; Nancy Breen; William W Davis; Marsha C Reichman Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-01 Impact factor: 4.254
Authors: Erica di Martino; Lesley Smith; Stephen H Bradley; Scott Hemphill; Judy Wright; Cristina Renzi; Rebecca Bergin; Jon Emery; Richard D Neal Journal: Br J Cancer Date: 2022-02-07 Impact factor: 9.075
Authors: Pierre Fwelo; Zenab I Yusuf; Abigail Adjei; Gabriel Huynh; Xianglin L Du Journal: Breast Cancer Res Treat Date: 2022-06-24 Impact factor: 4.624
Authors: Stephanie Navarro; Yifei Yang; Carol Y Ochoa; Aaron Mejia; Sue E Kim; Lihua Liu; Caryn Lerman; Albert J Farias Journal: JNCI Cancer Spectr Date: 2021-12-27
Authors: Adam C Mirando; Akash Patil; Christine I Rafie; Brian J Christmas; Niranjan B Pandey; Vered Stearns; Elizabeth M Jaffee; Evanthia T Roussos Torres; Aleksander S Popel Journal: Oncoimmunology Date: 2020-05-14 Impact factor: 7.723